Digital Commons Network^™

Diversity In Clinical Trials: The Case Of Drug Development For Rare Diseases, Allison Bowen

Business Administration Dissertations

Background: Approximately 40% of the population in the USA is comprised of minority racial and ethnic groups. However, despite this demographic representation, a study by Gray et al., (2022) found that out of the 53 novel drugs approved in 2020, 75% of the 32,000 participants were white. A study done by Woods-Burnham, et. al., (2021), found that enhancing racial and minority enrollment in clinical trials holds significant promise for improving survival outcomes within these communities. By prioritizing and dedicating resources to inclusive clinical trials, we can ensure greater access to state-of-the-art therapies for minority populations at high risk.

Patients afflicted …